Syndax Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael A. Metzger
- Full Time Employees
- 298
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 730 Third Avenue New York City NY United States of America 02451
- IPO Date
- Mar 2, 2016
- CIK
- 0001395937
- Website
- syndax.com
- Similar Companies
- Business
- Syndax Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical firm dedicated to developing advanced cancer treatments. The company’s portfolio features two key therapeutic candidates that have received FDA approval. Revuforj (revumenib), a selective menin inhibitor, is cleared for relapsed or refractory acute leukemias with KMT2A rearrangements and NPM1 mutations. Concurrently, Niktimvo (axatilimab), a monoclonal antibody that targets the CSF-1 receptor, is approved for treating chronic graft-versus-host disease in patients who have not responded to at least two prior systemic therapies. Both primary compounds are undergoing further clinical investigation for potential expansion into earlier treatment lines, combination regimens, and additional indications such as idiopathic pulmonary fibrosis. Syndax is also advancing Entinostat, a Class 1 HDAC inhibitor, in studies for various solid tumors and specific hematological malignancies. The company maintains strategic alliances, including a global collaboration with Incyte for axatilimab's development and commercialization, alongside other research partnerships. Incorporated in 2005, Syndax Pharmaceuticals is headquartered in Waltham, Massachusetts, concentrating on pioneering therapies to fulfill critical unmet medical requirements.
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Announces Participation in Upcoming Investor Conferences
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)